IRIS Research and Development | Plantation, FL

Research site

(Unclaimed)

Location

140 SW 84th Avenue, Suite B, Plantation, Florida, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

Baricitinib

Filgotinib

HZN-825

LY3009104

FDG

ABBV-599

BI 685509

ACTHar

Cenerimod

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 27 total trials

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Bas...

Enrolling

Diffuse Cutaneous Systemic Sclerosis

Sclerosis, Systemic

Drug: Placebo

Drug: HZN-825 QD

Locations recently updated

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS-1)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to seve...

Enrolling

Lupus Erythematosus, Systemic

Drug: Placebo

Drug: Cenerimod

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting

Psoriatic Arthritis

Biological: Placebo

Biological: Risankizumab

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting

Psoriatic Arthritis (PsA)

Biological: Placebo

Biological: Risankizumab

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling

Systemic Lupus Erythematosus

Other: Placebo

Drug: Afimetoran

Locations recently updated

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Enrolling

Scleroderma, Systemic

Drug: Placebo

Drug: Avenciguat (BI 685509)

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA-BRIDGE)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting

Rheumatoid Arthritis

Drug: Baricitinib

Drug: TNF Inhibitor

A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Enrolling

Rheumatoid Arthritis

Drug: Baricitinib

Drug: TNF Inhibitor

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting

Giant Cell Arteritis (GCA)

Drug: Upadacitinib

Other: Placebo

Locations recently updated

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

Primary Objectives:1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with...

Invitation-only

Diffuse Cutaneous Systemic Sclerosis

Sclerosis, Systemic

Drug: HZN-825

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis (FINCH 4)

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the...

Active, not recruiting

Rheumatoid Arthritis

Drug: Filgotinib

Drug: Placebo to match filgotinib

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling

Systemic Lupus Erythematosus

Drug: Upadacitinib

Drug: Placebo

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis (RESET-RA)

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderat...

Active, not recruiting

Rheumatoid Arthritis

Procedure: Implant Procedure

Drug: Conventional Synthetic DMARD